Cynosure Lutronic reports accelerating adoption of its XERF monopolar radiofrequency platform across North American medspas and aesthetic practices. The device is positioned as a leading fractional RF option in a market segment dominated by InMode's Forma, Cutera's Xeo, and Synergist platforms.
Devices & Tech
Cynosure Lutronic's XERF Monopolar RF Platform Gains Rapid Adoption Across North America
Fractional RF device shows accelerating uptake in the competitive energy-device market.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
XERF monopolar RF adoption accelerates, intensifying competition in the fractional RF segment and compressing device acquisition economics.
Monopolar RF devices target skin tightening and collagen remodeling with lower downtime than ablative lasers, making them high-margin consumable-light procedures for practices. XERF's uptake reflects both competitive pricing and Cynosure Lutronic's distribution strength through existing laser and light-source relationships. For practices evaluating RF platforms, the competitive intensity in fractional RF—with multiple cleared devices and aggressive marketing—continues to compress acquisition costs and service terms, but also fragments the installed base and complicates vendor lock-in strategies.
Source: original report ↗
Frequently asked questions
What is monopolar RF and how does it differ from other radiofrequency devices?
Monopolar RF uses a single electrode to deliver radiofrequency energy deep into the dermis for skin tightening and collagen remodeling. Unlike bipolar or multipolar RF, monopolar penetrates deeper with less surface cooling required, making it effective for larger treatment areas with lower downtime than ablative lasers.
How much does the Cynosure Lutronic XERF cost compared to competitors?
While specific pricing isn't disclosed, XERF is positioned as competitively priced in the fractional RF market. The competitive intensity among platforms like InMode's Forma, Cutera's Xeo, and Synergist has compressed acquisition costs and service terms across the segment.
What are the profit margins on monopolar RF treatments?
Monopolar RF procedures are high-margin for practices because they require minimal consumables compared to laser treatments. The combination of low material costs and strong patient demand for skin tightening with minimal downtime makes RF a profitable recurring revenue stream.
Is XERF FDA cleared and what conditions does it treat?
XERF is positioned as a leading fractional RF platform with rapid North American adoption across medspas and aesthetic practices. The device targets skin tightening and collagen remodeling, offering lower downtime than ablative laser alternatives.
Which RF device should I buy for my medspa—XERF, Forma, or Xeo?
XERF, InMode's Forma, Cutera's Xeo, and Synergist are all cleared fractional RF options with different strengths. Your choice should factor in acquisition cost, service terms, existing vendor relationships, and whether you prioritize deeper penetration (monopolar) versus targeted surface treatment.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.